Human epidermal growth factor receptor 2 (HER2) is an important biomarker for detection and treatment of different types of cancers such as breast, ovarian, stomach cancer. In this study, we developed a monoclonal antibody against the extracellular domain (ECD) of HER2 biomarker of breast cancer. For this purpose, the ECD-HER2 gene was amplified and cloned into an expression vector. Gene was generated in Escherichia coli BL21 (DE3) strain for expression of recombinant protein. The expressed protein was separated by SDS-PAGE and detected by anti-his monoclonal antibody in immunoblotting. Hybridoma cells were obtained by fusing myeloma cells with mouse spleen cells injected with recombinant ECD-HER2 and screened by ELISA for the production of monoclonal antibody. The results indicate that out of three candidate hybridoma cells one clone (1E7) was producing the highest titer and antibody specificity was envisioned in ELISA results. In vivo scaling up culture of hybridoma cells in BALB/C mice lead to significant increase in the monoclonal antibody concentration up to 16 mg/ml. Immunochemical methods demonstrated the specificity of developed antibody against ECD-HER2 protein.
AbeldenovS. and KhassenovB., Cloning, expression and purification of recombinant analog of Taq DNA polymerase, Biotechnology. Theory and Practice1 (2014), 12–16.
2.
AliS.M.LeitzelK.ChinchilliV.M.EngleL.DemersL.HarveyH.A.CarneyW.AllardJ.W. and LiptonA., Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer, Clin Chem48(8) (2002), 1314–1320.
3.
AtalayG.CardosoF.AwadaA. and PiccardM., Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer, Ann. Oncol14 (2003), 1346–1363.
4.
BajajM.WaterfieldM.D.SchlessingerJ.TaylorW.R. and BlundellT., On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors, Biochim Biophys Acta916(2) (1987), 220–226.
5.
BerghoffA.S.BartschR.PreusserM.RickenG.StegerG.G.Bago-HorvathZ.RudasM.StreubelB.DubskyP.GnantM.FitzalF.ZielinskiC.C. and BirnerP., Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients, Breast23(5) (2014), 637–643.
6.
BradfordM.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal Biochem72 (1976), 248–254.
7.
CarneyW.P.BernhardtD. and JasaniB., Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients, Biomark Cancer5 (2013), 31–39.
8.
ChoH.S.MasonK.RamyarK.StanleyA.GabelliS.DenneyD. and LeahyD., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature421(6924) (2003), 756–760.
9.
CodingJ., Antibody production by hybridoma, J. Immunol. Meth39(1) (1980), 285–308.
10.
CoussensL.Yang-FengT.L.LiaoY.C.ChenE.GrayA.McGrathJ.SeeburgP.H.LibermannT.A.SchlessingerJ.FranckeU. et al., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science230(4730) (1985), 1132–1139.
11.
CrestiN.LeeJ.RourkeE.TelevantouD.JamiesonD.VerrillM. and BoddyA.V., Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer, Eur J Cancer55 (2016), 27–37.
12.
EliasS.G.AdamsA.WisnerD.J.EssermanL.J.van’t VeerL.J.MaliW.P.GilhuijsK.G. and HyltonN.M., Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis, Cancer Epidemiol Biomarkers Prev23(8) (2014), 1464–1483.
13.
FranklinM.C.CareyK.D.VajdosF.F.LeahyD.J.de VosA.M. and SliwkowskiM.X., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, Cancer Cell5 (2004), 317–328.
14.
SimonR., Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, in: Biomarkers in Breast CancerGaspariniG. and HayesD., eds, Humana Press Ink, Totowa, NJ, 2007, pp. 333.
15.
GutierrezC. and ShiffC., HER2: biology, detection, and clinical implications, Arch Pathol Lab Med135(1) (2011), 55–62.
16.
LaemmliU.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature227(5259) (1970), 680–685.
17.
LiY.M.PanY.WeiY.ChengX.ZhouB.P.TanM.ZhouX.XiaW.HortobagyiG.N.YuD. and HungM.C., Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis, Cancer Cell6(5) (2004), 459–469.
18.
MarmorM.D.SkariaK.B. and YardenY., Signal transduction and oncogenesis by ErbB/HER receptors, Int J Radiat Oncol Biol Phys58(3) (2004), 903–913.
19.
ManiatisT.FritschE.F. and SambrookJ., Molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, New York: Cold Spring Harbor Laboratory, 1987, 545.
20.
MussakhmetovA.AbeldenovS. and KhassenovB., Purification of recombinant Pfu DNA polymerase by double step affinity chromatography, Biotechnology. Theory and Practice2 (2014), 42–47.
21.
OiV.T. and HerzenbergL.A., Immunoglobulin- producing hybrid cell lines, in: Selected Methods in Cellular ImmunologyMishellB.B. and ShiigiS.M., eds, W.H. Freeman New York, 1980, pp. 351–352.
22.
PichonM.F.HaceneK.GuepratteS. and NeumannR., Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients, Clin Lab.50(3–4) (2004), 163–170.
23.
RosenL.AshurstH. and ChapL., Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review, Oncologist15 (2010), 216–235.
24.
SonH.S.ShinY.M.ParkK.K.SeoK.W.YoonK.Y.JangH.K.LeeS.H.YangS.I. and KimJ.H., Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection, J Gastric Cancer14(3) (2014), 180–186.
25.
WangD.ZhuH.YeQ.WangC. and XuY., Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer, Medicine (Baltimore)95(8) (2016), e2803.
